R 172355Z JUN 20
MSGID/GENADMIN/CMC WASHINGTON DC PPO//
SUBJ/U.S. MARINE CORPS GUIDANCE FOR DEPLOYMENT AND REDEPLOYMENT OF INDIVIDUALS AND UNITS, SURVEILLANCE AND SCREENING AND TESTING, AS WELL AS LABORATORY DIAGNOSTIC TESTING DURING THE NOVEL CORONAVIRUS DISEASE 2019 PANDEMIC//
NARR/REF A IS UNDER SECRETARY OF DEFENSE FOR PERSONNEL AND READINESS (USD(P&R)) MEMORANDUM, FORCE HEALTH PROTECTION GUIDANCE (SUPPLEMENT 9)-DEPARTMENT OF DEFENSE GUIDANCE FOR DEPLOYMENT AND REDEPLOYMENT OF INDIVIDUALS AND UNITS DURING THE NOVEL CORONAVIRUS DISEASE 2019 PANDEMIC. REF B IS USD(P&R) MEMORANDUM, FORCE HEALTH PROTECTION (SUPPLEMENT 11)-DEPARTMENT OF DEFENSE GUIDANCE FOR CORONAVIRUS DISEASE 2019 SURVEILLANCE AND SCREENING WITH TESTING. REF C IS USD(P&R) MEMORANDUM, FORCE HEALTH PROTECTION GUIDANCE (SUPPLEMENT 10)-DEPARTMENT OF DEFENSE GUIDANCE FOR CORONAVIRUS DISEASE 2019 CLINICAL LABORATORY DIAGNOSTIC TESTING SERVICES. REF D IS NAVADMIN 155/20, U.S. NAVY COVID-19 STANDARDIZED OPERATIONAL GUIDANCE. REF E IS DODI 6490.03, DEPLOYMENT HEALTH. REF F IS DOD COVID-19 TASK FORCE MEMORANDUM, DOD COVID-19 TASK FORCE LABORATORY TESTING LINE OF EFFORT. REF G IS SECRETARY OF DEFENSE MEMORANDUM, GUIDANCE FOR COMMANDERS ON RISK-BASED CHANGING OF HEALTH PROTECTION CONDITION LEVELS DURING THE CORONAVIRUS DISEASE 2019 PANDEMIC. REF H IS USD(P&R) MEMORANDUM, FORCE HEALTH PROTECTION GUIDANCE (SUPPLEMENT 8)-DEPARTMENT OF DEFENSE GUIDANCE FOR PROTECTING PERSONNEL IN WORKPLACES DURING THE RESPONSE TO CORONAVIRUS DISEASE 2019 PANDEMIC. REF I IS USD(P&R) MEMORANDUM, FORCE HEALTH PROTECTION GUIDANCE (SUPPLEMENT 5)-DEPARTMENT OF DEFENSE GUIDANCE FOR MOVEMENT AND MEDICAL TREATMENT OF COVID-19 PATIENTS, SYMPTOMATIC PERSONS UNDER INVESTIGATION, OR POTENTIALLY EXPOSED COVID-19 PERSONS. REF J IS DON(M&RA) POLICY MEMORANDUM, DEPARTMENT OF DEFENSE GUIDANCE FOR DEPLOYMENT AND REDEPLOYMENT OF INDIVIDUALS AND UNITS DURING THE NOVEL CORONAVIRUS DISEASE 2019 PANDEMIC. REF K IS DON(M&RA) MEMORANDUM, DEPARTMENT OF THE NAVY GUIDANCE FOR CLINICAL LABORATORY TESTING, SURVEILLANCE, AND SCREENING DURING THE NOVEL CORONAVIRUS DISEASE 2019 PANDEMIC. A DETAILED SUMMARY DEPICTING THE ALIGNMENT OF THIS MARADMIN WITH THE REFERENCES IS LOCATED ON THE MARINE CORPS CRISIS ACTION TEAM (MCCAT) UNCLASSIFIED SHAREPOINT AT HTTPS:(SLASH)(SLASH)EIS.USMC.MIL/SITES/HQMCPPO/MCCAT/SITEPAGES/HOME.ASPX UNDER THE POLICY AND REFERENCES LINK.//
POC/HQMC MCCAT OPERATIONS OFFICER/UNIT: PP&O POC/F/TEL: (703) 692-4302/NIPR EMAIL: SMB_HQMC_MCCAT@USMC.MIL//
GENTEXT/REMARKS/1. This MARADMIN provides Service-level guidance to USD(P&R) Memorandum, Force Health Protection Guidance (Supplement 9)-Department of Defense Guidance for Deployment and Redeployment of Individuals and Units during the Novel Coronavirus Disease 2019 (COVID-19) Pandemic (reference (a)), USD(P&R) Memorandum, Force Health Protection Guidance (Supplement 11)-Department of Defense Guidance for COVID-19 Surveillance and Screening with Testing (reference (b)), and USD(P&R) Memorandum, Force Health Protection Guidance (Supplement 10)-Department of Defense Guidance for Coronavirus Disease 2019 Clinical Laboratory Diagnostic Testing Services (reference (c)).
1.A.1. Reference (a) reinforces and supports the Secretary of Defense’s priorities for the Coronavirus disease 2019 response: 1) protect military and civilian personnel and their families; 2) safeguard national security capabilities; and 3) support the whole-of-nation response to the pandemic. The policy covers deployment to, and redeployment from, any operational area, including COVID-19 operational areas, to home station for all Active Component, Reserve Component Marines, Sailors, and Marine Corps and Navy civilian employees. “COVID-19 operational area” means a geographic area or location, overseas or in the United States, where Marine units are deployed to conduct operations in a COVID-19 Pandemic environment, including operational support in response to COVID-19. The term “home station” means the installation from which the deployment began, or in in the case of deployed Marine Reserve members, their originating unit location or home, if not deployed as part of an assigned unit.
1.A.2. Reference (b) outlines the surveillance strategy for the COVID-19 Pandemic response, including medical screening, asymptomatic testing, and sentinel surveillance testing and augments guidance for diagnostic testing in reference (c) for all Active Component, Reserve Component Marines and Sailors, as well as Marine Corps and Navy civilian employees, and family members. This strategy is designed to break the chain of disease transmission to reduce risk to the force and DoD missions through a multi-faceted approach to include clinical diagnostic testing, health surveillance activities, tiered testing, contact tracing, sentinel surveillance, and serologic testing. The Marine Corps will employ health surveillance, screening, contact tracing, and sentinel surveillance to decrease operational risk, while continuing all appropriate clinical diagnostic testing. Additionally, the Marine Corps will conduct testing of selected asymptomatic individuals, determined appropriate by healthcare professionals as part of our risk reduction and surveillance strategy in coordination with the DoD COVID-19 Task Force Diagnostics and Testing Line of Effort (CVTF-LAB). Testing will be prioritized by tier beginning with Tier 1 (Critical National Capabilities). Tier 2 (Engaged Fielded Forces), Tier 3 (Forward Deployed/Redeploying Forces) and Tier 4 (All Other Forces) will begin asymptomatic testing, as determined appropriate by a healthcare professional, after Tier 1 testing reaches steady state and all necessary testing materiel is available.
1.A.3. Reference (c) provides guidance on clinical and diagnostic COVID-19 testing for eligible persons with a DoD connection suspected of having contracted COVID-19, and applies Centers for Disease Control and Prevention (CDC) testing guidance to the DoD context. The Marine Corps will continue to employ clinical diagnostic testing in accordance with this guidance. This guidance does not prohibit or impede surveillance, screening, and asymptomatic testing conducted to decrease operational risk within the Marine Corps. The reference also discusses eligibility for testing of the Reserve Component, DoD civilians, family members, employees of DoD contractors, and local national employees in locations outside the United States.
2. Mission. The Marine Corps will implement the guidance provided in reference (a) through reference (c) to protect the force while continuing the mission of the Corps.
3.A. Commander’s Intent.
3.A.1. Purpose. To promulgate updated Commandant of the Marine Corps (CMC) guidance for deployment and redeployment of individuals and units, surveillance and screening and testing, as well as clinical laboratory diagnostic testing during the novel Coronavirus disease 2019 pandemic.
3.A.2. Method. The Commandant has identified COVID-19 as a threat to the health and well-being of the Marine Corps. The Marine Corps will take measured steps to protect all Marines, Sailors, dependents, government civilians, and contract worker personnel. Informed by Office of the Secretary of Defense (OSD) and Department of the Navy (DON) guidance and actions, the intent of this message is to protect the force and preserve our capability to accomplish the mission of the Marine Corps.
3.A.3. End State. The U.S. Marine Corps is postured to mitigate, contain, respond to, and recover from the effects of this public health challenge, and is capable of continued execution of assigned mission.
3.B. Concept of Operations. The Marine Corps will institute the guidance contained in the MARADMIN and comply with the deployment and redeployment of individuals and units during the COVID-19 Pandemic as required in reference (a) through reference (c). Concurrent with this MARADMIN release, the OSD has directed Service-level data collection and analysis to inform and determine the optimal Restriction of Movement (ROM) duration and testing interval. Commanders should be prepared to adjust ROM and testing procedures based on pending results of the data analysis. Should future OSD-level and/or Department of Navy guidance deviate from ROM and testing protocols contained herein, supplemental guidance to the force will follow.
3.C.1. Total Force.
3.C.1.A.1. The Marine Corps, as a force provider, is responsible for providing medically ready forces that are, to the greatest extent possible, free from infection from COVID-19 to both Functional Combatant Commands (FCC) and Geographic Combatant Commands (GCC). Deploying and redeploying forces will execute testing for 100 percent of personnel. The requirement to request tests through the applicable Medical Treatment Facility, acquire, and provision tests resides with the force provider. When and where inventory is not available or when Host Nation or GCC protocols do not mandate testing, units are expected to exercise prudent screening and mitigation measures if moving between GCC or to offset test capacity shortfalls. All individuals and units embarking U.S. Navy vessels shall comply with the requirements in reference (d).
3.C.1.A.2. Marine Corps installations and Marine Corps units will conduct sentinel surveillance testing of one percent of Marines, Sailors, and Marine Corps civilian employees every 14 days among Tier 1-4 populations. Sentinel surveillance testing is not applicable to Reserve units conducting Inactive Duty Training (IDT) or Annual Training (AT); however, sentinel surveillance testing will apply to activated units.
3.C.1.A.3. Conduct sentinel surveillance testing of 10 percent of selected populations living in congregate settings every 14 days.
3.C.1.A.4. Conduct sentinel surveillance testing of 10 percent of clinical health care personnel every 14 days.
3.C.1.A.5. The results of tests associated with sentinel surveillance will be provided to the tested individuals.
3.C.1.A.6. Contact tracing is required on all COVID-19 cases identified via screening and surveillance activities. Follow-on quarantine or isolation measures will be implemented based on the results of screening and/or surveillance activities. Asymptomatic close contacts will be managed in accordance with reference (c).
3.C.1.B.1 Deployment and Redeployment Requirements.
3.C.1.B.1.A. All deploying and redeploying Marines, Sailors, and Marine Corps and Navy civilian employees will complete Force Health Protection (FHP) pre-deployment requirements in accordance with reference (e), including screening for COVID-19 exposure, symptoms, and testing (as contained herein) consistent with DoD COVID-19 testing guidance set forth in reference (b) and reference (f).
3.C.1.B.1.B All Marine Corps units will ensure that deploying and redeploying Marines, Sailors, and Marine Corps and Navy civilian employees are appropriately screened for exposure history, temperature check, COVID-19 signs and symptoms (e.g. fever, chills, rigors, muscle pain, headache, sore throat, new smell and taste disorders, coughing, or shortness of breath), and review of any past COVID-19 testing results at the assigned place of duty or point of embarkation.
3.C.1.B.1.C A DoD healthcare provider will be available for consultation if unable to directly administer the screening. An evaluation by a healthcare provider, including COVID-19 diagnostic testing if indicated, will be conducted for individuals with a fever or who indicate any affirmative responses to the screening questions in accordance with reference (c).
3.C.1.B.1.D. All units will ensure symptomatic Marines, Sailors, and Marine Corps and Navy civilian employees consult with a healthcare provider for further assessment and/or testing. Marines, Sailors, and Marine Corps and Navy civilian employees who meet the clinical case definition of a “probable” infection (absent a diagnostic test result) or who are confirmed COVID-19 positive during screening will be isolated per guidance found in reference (a).
3.C.1.B.2. Additional Redeployment Requirements.
3.C.1.B.2.A. All redeploying Marines, Sailors, and Marine Corps and Navy civilian employees will complete a Post-Deployment Health Assessment (DD Form 2796) and Post-Deployment Health Reassessment (DD Form 2900) in accordance with reference (e).
3.C.1.C. Restriction of Movement (ROM).
3.C.1.C.1. Deployment Requirements.
3.C.1.C.1.A. All Marines and Sailors deploying outside the United States, whether to a COVID-19 operational area or not, will undergo a mandatory 14-day ROM prior to deployment except when ROM has been arranged in country. All deploying Marine Corps and Navy civilian employees and contractor personnel are strongly encouraged to undergo a 14-day ROM as well.
3.C.1.C.2. Redeployment Requirements.
3.C.1.C.2.A. Marines and Sailors redeploying, whether from a COVID-19 operational area or not, will undergo risk-based screening and a 14-day ROM is required. The 14-day ROM will be performed at a predetermined location to include home station, the Marine or Sailor’s residence, or other suitable domicile. All redeploying Marine Corps and Navy civilian employees and contractors will be assessed to determine if a voluntary ROM is recommended.
3.C.1.C.2.B. Additional ROM actions for redeploying personnel are contained in reference (a).
3.C.1.C.3. Reserve ROM Considerations.
3.C.1.C.3.A. Reserve Marines will perform ROM while still on orders, prior to the Marine’s demobilization.
3.C.1.C.3.B. Reserve IDT and AT periods conducted within CONUS, Alaska, Hawaii, and Puerto Rico do not constitute a deployment for purposes of conducting 14-day ROM. All Reserve personnel will be screened prior to departing for IDT or AT.
3.C.1.C.3.C. Reserve Marines in support of another Department or Agency will complete any required health and ROM measures, including home-based quarantine or self-monitoring, prior to the end of the period of support to that other Department or Agency.
3.C.1.C.4. ROM locations for units and individuals will be coordinated with the losing and gaining organizations.
3.D. Coordinating Instructions.
3.D.1. Deploying units and individuals shall confirm host nation entry requirements to avoid duplicative risk mitigation measures (i.e. ROM and testing).
3.D.2. Operational units can request a deployment ROM waiver if mission requirements dictate an expedited deployment. The approval authority for a ROM waiver is the Secretary of Defense.
3.D.3. Travel to the deployment location should, to the maximum extent possible, minimize the risk of deploying Marines, Sailors, and Marine Corps and Navy civilian employees of being exposed to or infected with COVID-19.
3.D.4. Refer to reference (g) for ROM considerations when deploying or redeploying to a location where the Health Protection Condition differs from that of the origin.
3.D.5. Marines, Sailors, and Marine Corps and Navy civilian employees deemed mission essential personnel and those in critical operational or critical infrastructure positions, who have redeployed to home station, may be permitted to continue work following potential exposure to the virus, provided they remain asymptomatic, wear a face covering, practice social distancing, and an exception to continue work is granted in accordance with reference (h).
3.D.6. Symptomatic, probable, or confirmed COVID-19 Marines, Sailors, and Marine Corps and Navy civilian employees will be placed into isolation. Such individuals will be managed, tested, and released from isolation in accordance with reference (a). In addition, installation and unit commanders will consider the most recent Center for Disease Control and Prevention (CDC) guidance for releasing Marines, Sailors, and Marine Corps civilian employees placed into isolation in order to return back to work.
3.D.7. Marine Corps and Navy civilian employees and contractor personnel associated with Tier 1-3 populations are strongly recommended to follow guidance and practice ROM in accordance with reference (b).
4. Administration and Logistics.
4.A.1. This MARADMIN directs continued reporting of Tiers 1-3 (Tier 4, if directed) testing requirements for Service-retained forces and accessions training to the Joint Staff Crisis Management Team, including requirements for Reserve forces and covered civilian personnel in accordance with guidance contained in reference (f).
4.A.2. Reference: The latest Force Health Protection Supplement guidance can be found at https:(slash)(slash)www.defense.gov/Explore/Spotlight/Coronavirus/.
4.A.3. Additional CDC COVID-19 updates are at
4.B.1. Redeployment or other movement of symptomatic, probable, or confirmed COVID-19 positive individuals will be limited and implemented in accordance with reference (i).
4.B.2. COVID-19 testing and surveillance will be performed with a laboratory test under a U.S. Food and Drug Administration emergency use authorization to detect COVID-19 nucleic acid. Routing requests for testing supplies is through the Chain of Command, identifying the total requirement, e.g., the mission, number of tests, and NLT completion date of testing. This information will be submitted to the unit’s respective Marine Centered Medical Home (MCMH). Due to the scarcity of supplies, this should occur as soon as the information is available. The MCMH will register the requirement with the local Military Medical Treatment Facility who then places the order for supplies and plans for testing.
4.B.3. Asymptomatic Marine Corps and Navy civilian employees and contractors in Tier 1-3 may be offered testing conducted in accordance with reference (b).
4.C. This MARADMIN has been coordinated with HQMC, Health Services-Preventative Medicine, HQMC Judge Advocate Division, Communication Directorate, Counsel for the CMC, DC&CD&I, DC I, DC I&L, DC M&RA, DC P&R, Marine Corps Installations Command, and Office of Legislative Affairs.
4.D. Terms and Definitions.
4.D.1. COVID-19 CASE: A member designated by a medical provider by one of two methods; 1) a positive COVID-19 laboratory test, or 2) assessed as presumed positive per the council of state and territorial epidemiologist (CSTE) criteria for a probable case.
4.D.2. HIGH-RISK PERSONNEL: Those individuals, designated by a medical provider that meet the CDC high-risk criteria available at: https:(slash)(slash)www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html. Frequently reference this list because it evolves based on new information related to COVID-19.
4.D.3. CLOSE CONTACT: Individuals identified as being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time (>15 minutes). Close contact can occur while caring for, living with, visiting, working with, or sharing a densely populated space with a COVID-19 case. Close contact also covers individuals who come into direct contact (e.g., being coughed or sneezed upon by a COVID-19 case). Determination of close contact presumes the interaction transpired during the COVID-19 cases potentially infectious period, currently defined as 48 hours prior to symptom onset (or positive test if asymptomatic) to the time the COVID-19 case is placed in isolation. Examples specific to the shipboard environment include individuals within the COVID-19 case’s berthing area assigned an adjacent rack, including directly across a narrow aisle and prolonged interaction within relatively confined spaces internal to the ship (e.g., work space, galley, gym, smoking deck, chapel, etc.).
4.D.4. MEDICAL SCREENING: COVID-19 medical screening should include evaluation for both typical and atypical symptoms. Typical symptoms of COVID-19 include cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, gastrointestinal distress, and recent loss of taste or smell. Atypical symptoms of COVID-19 include, but are not limited to, sore throat, rhinorrhea (runny nose), nasal congestion, nausea, diarrhea, headache, increased confusion, dizziness, and malaise. A complete list of COVID-19 symptoms can be found at: https:(slash)(slash)www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
4.D.5. SELF-MONITORING: Per the CDC, self-monitoring includes assessing onset of fever by taking one’s temperature twice a day and remaining alert for the onset of cough or breathing difficulty. CDC defines fever as temperature greater than or equal to 100.4 F (38C) degrees. Individuals that develop fever, cough, or breathing difficulty should immediately self-isolate, limit contact with others, and seek advice by telephone from a healthcare provider to determine if further medical evaluation is required.
4.D.6. SENTINEL SURVEILLANCE TESTING: The act of testing for infections in selected populations to detect disease early and direct public health action. Effective sentinel surveillance for COVID-19 requires testing asymptomatic persons; these persons should be in populations with a higher likelihood of infection and where actions can prevent widespread transmission.
4.D.7. RESTRICTION OF MOVEMENT (ROM): Limiting movement of an individual or group to prevent or diminish the transmission of a communicable disease, including limiting ingress and egress to, from, or on a military installation, isolation, quarantine, and conditional release.
4.D.8. ISOLATION: The separation of an individual or group infected or reasonably believed as infected with a communicable disease from those who are healthy in such a place and manner to prevent the spread of the communicable disease.
4.D.9. QUARANTINE: The separation of an individual or group that has been exposed to a communicable disease, but is not yet ill, from others who have not been so exposed, in such manner and place to prevent the possible spread of the communicable disease.
4.D.10 CONGREGATE SETTING: A congregate setting is an environment where a number of people reside, meet, or gather in close proximity for either a limited or extended period of time.
5. Command and Signal.
5.A. Command. This MARADMIN applies to the Total Force.
5.B. Signal. This MARADMIN is effective upon release. Ensure widest dissemination.
6. This message is approved for release by LtGen G. W. Smith, Jr. Deputy Commandant, Plans, Policies, and Operations.//